EUR 6.1
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 24.72 Million EUR | -183.95% |
2022 | 19.02 Million EUR | 37.46% |
2021 | 19.64 Million EUR | 25.1% |
2020 | 12.86 Million EUR | -24.44% |
2019 | 17.37 Million EUR | 1.77% |
2018 | 18.41 Million EUR | 11.56% |
2017 | 13.92 Million EUR | 67.38% |
2016 | 7.58 Million EUR | -14.12% |
2015 | 12.63 Million EUR | 3.29% |
2014 | 2.33 Million EUR | 21.24% |
2013 | 10.09 Million EUR | 6.37% |
2012 | 9.48 Million EUR | 1.65% |
2011 | 8.52 Million EUR | 374.61% |
2010 | -3.39 Million EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 Q4 | -26.5 Million EUR | 0.0% |
2023 Q2 | 10.43 Million EUR | 0.0% |
2022 Q2 | 10.87 Million EUR | 0.0% |
2022 FY | - EUR | 37.46% |
2022 Q4 | 10.93 Million EUR | 0.0% |
2021 Q2 | 7.9 Million EUR | 0.0% |
2021 FY | - EUR | 25.1% |
2021 Q4 | 11.59 Million EUR | 0.0% |
2020 Q2 | 8.84 Million EUR | 0.0% |
2020 Q4 | 5.52 Million EUR | 0.0% |
2020 FY | - EUR | -24.44% |
2019 FY | - EUR | 1.77% |
2019 Q2 | 17.73 Million EUR | 0.0% |
2019 Q4 | 2.89 Million EUR | 0.0% |
2018 Q4 | 13.18 Million EUR | 0.0% |
2018 FY | - EUR | 11.56% |
2018 Q2 | 5.52 Million EUR | 0.0% |
2017 Q4 | 13.87 Million EUR | 0.0% |
2017 Q2 | 4.29 Million EUR | 0.0% |
2017 FY | - EUR | 67.38% |
2016 Q2 | 4.03 Million EUR | 0.0% |
2016 FY | - EUR | -14.12% |
2016 Q4 | 6.81 Million EUR | 0.0% |
2015 Q4 | 6.51 Million EUR | 0.0% |
2015 FY | - EUR | 3.29% |
2015 Q2 | 6.12 Million EUR | 0.0% |
2014 FY | - EUR | 21.24% |
2014 Q4 | 7.02 Million EUR | 0.0% |
2014 Q2 | 5.21 Million EUR | 0.0% |
2013 Q4 | 6.09 Million EUR | 0.0% |
2013 Q2 | 3.99 Million EUR | 0.0% |
2013 FY | - EUR | 6.37% |
2012 Q1 | 2.13 Million EUR | 0.0% |
2012 Q3 | 2.36 Million EUR | 0.0% |
2012 Q4 | 2.36 Million EUR | 0.0% |
2012 FY | - EUR | 1.65% |
2012 Q2 | 2.36 Million EUR | 10.85% |
2011 Q2 | 2.13 Million EUR | 350.66% |
2011 Q1 | -849.75 Thousand EUR | 0.0% |
2011 Q4 | 2.13 Million EUR | 0.0% |
2011 FY | - EUR | 374.61% |
2011 Q3 | 2.13 Million EUR | 0.0% |
2010 Q4 | -849.75 Thousand EUR | 0.0% |
2010 FY | - EUR | 0.0% |
2010 Q2 | -849.75 Thousand EUR | 0.0% |
2010 Q3 | -849.75 Thousand EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Crossject Société Anonyme | -7.29 Million EUR | 438.925% |
Safe Orthopaedics SA | -5.62 Million EUR | 539.687% |
Spineway SA | -4.79 Million EUR | 616.134% |
Sartorius Stedim Biotech S.A. | 777.2 Million EUR | 96.818% |
EssilorLuxottica Société anonyme | 6.18 Billion EUR | 99.6% |
bonyf N.V. | -39.89 Thousand EUR | 62084.118% |